Recherche

Afficher tous les résultats pour

Accueil

Personne

Patrick Aebischer

À propos
Confidentialité
Mentions légales

Graph Chatbot

Publications associées (172)

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

Patrick Aebischer, Nicole Déglon, Didier Trono

Lentiviral delivery of glial cell line-derived neurotrophic factor (lenti-GDNF) was tested for its trophic effects upon degenerating nigrostriatal neurons in nonhuman primate models of Parkinson's disease (PD). We injected lenti-GDNF into the striatum and ...

American Association for the Advancement of Science2000

Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease

Patrick Aebischer, Nicole Déglon

Huntington's disease (HD) is an inherited disorder characterized by cognitive impairments, motor deficits, and progressive dementia. These symptoms result from progressive neurodegenerative changes mainly affecting the neostriatum. This pathology is fatal ...

2000

Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis

Patrick Aebischer

Impairment of pulmonary function is a major prognostic indicator in amyotrophic lateral sclerosis (ALS). Forced vital capacity (FVC) and maximal voluntary ventilation (MVV) decline linearly and are commonly used to assess disease progression. The aim of th ...

1999

Highlights of the cell transplantation meeting at Montreux, March 1999

Patrick Aebischer, Bernard Schneider

1999

Treatment of diseases of the central nervous system using encapsulated cells

Patrick Aebischer

1999

Application of Teflon-AF thin films for bio-patterning of neural cell adhesion

Patrick Aebischer, Marc Ilegems

Teflon AF, an amorphous copolymer of polytetrafluoroethylene (PTFE) with 2,2-bis(triflouromethyl)-4,5-difluoro-1, 3-dioxole, has been receiving widespread attention in the opto-electronics industries and elsewhere for its superior optical and dielectric pr ...

1998

In vivo performance of a new biodegradable polyester urethane system used as a nerve guidance channel

Patrick Aebischer

Biodegradable nerve guidance channels (NGCs) represent a promising alternative to current clinical nerve repair procedures. To be suitable as a NGC material, the polymer system should possess elastomeric properties and degrade at a defined rate without int ...

1998

A gene therapy approach for the treatment of amyotrophic lateral sclerosis and Parkinson's disease

Patrick Aebischer, Nicole Déglon

1998

Intrathecal implants of bovine chromaffin cells alleviate mechanical allodynia in a rat model of neuropathic pain

Patrick Aebischer

Intrathecal implants of adrenal chromaffin cells are known to release analgesic substances such as catecholamines and opioid peptides. In the present study, bovine chromaffin cells were encapsulated in a permselective polymer membrane which protects the ce ...

1998

Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice

Patrick Aebischer, Jean-Charles Bensadoun

Normal cellular metabolism produces oxidants which are neutralized within cells by antioxidant enzymes and other antioxidants. An imbalance between oxidants and antioxidants has been postulated to lead to the degeneration of specific populations of neurons ...

1998

Three-dimensional extracellular matrix engineering in the nervous system

Patrick Aebischer

Growing neurites are guided through their environment during development and regeneration via different cellular and extracellular matrix (ECM) molecular cues. To mimic cell-matrix interactions, a three-dimensional (3D) hydrogel-based ECM equivalent contai ...

1998

Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy

Patrick Aebischer

To determine whether neurturin (NTN), a recently identified homologue of glial cell line-derived neurotrophic factor (GDNF), is able to preserve tyrosine hydroxylase immunoreactivity (TH-IR) in a rat model of Parkinson's disease, polymer encapsulated cells ...

1998

Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts

Patrick Aebischer, Nicole Déglon, Bernard Schneider

The transplantation of polymer encapsulated myoblasts genetically engineered to secrete erythropoietin (Epo) may obviate the need for repeated parenteral administration of recombinant Epo as a treatment for chronic renal failure, cancer or AIDS-associated ...

1998

Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization

Patrick Aebischer

Glial cell line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor which has been purified on the basis of its ability to promote the survival of dopaminergic neurons in vitro. GDNF has subsequently been cloned and its sequence shown to be ...

1997

The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis

Patrick Aebischer, Eric Garrison Fine

A subpopulation of familial cases of amyotrophic lateral sclerosis has been linked to mutations in the gene encoding Cu/Zn superoxide dismutase (SOD1). There is in vitro evidence that certain SOD1 mutants, in addition to their normal dismutation function, ...

1997

GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine

Patrick Aebischer

Parkinson's disease (PD) is characterized by the progressive loss of the substantia nigra (SN) dopaminergic neurons projecting to the striatum. Neurotrophic factors may have the potential to prevent or slow down the degenerative process occurring in PD. To ...

1997

A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension

Patrick Aebischer, Nicole Déglon

Current therapy for several forms of anemia involves a weekly regime of multiple subcutaneous injections of recombinant human erythropoietin (hEpo). In an effort to provide a physiologically regulated administration of erythropoietin, we are developing cel ...

1997

Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience

Patrick Aebischer, Julien Favre

BACKGROUND: Chromaffin cells from the adrenal gland secrete a mixture of compounds that have a strong analgesic effect, especially when administered intrathecally. Many studies in animal models have shown that discordant xenogeneic cell isolates, including ...

1996

Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients

Patrick Aebischer, Nicole Déglon

Neuronal growth factors hold promise for providing therapeutic benefits in various neurological disorders. As a means of ensuring adequate central nervous system delivery of growth factors and minimizing significant adverse side effects associated with sys ...

1996

Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro

Patrick Aebischer

We have previously shown that glial cell line-derived neurotrophic factor (GDNF), in addition to promoting the survival of dopaminergic neurons in cultures from embryonic rat ventral mesencephalon,also increases the activity of choline acetyltransferase (C ...

1996

Page 8 sur 9